Skip to main content

Table 1 Overall demographics and exposures during international travel, number (%) of subjects (N = 58)

From: Antimicrobial resistance acquisition after international travel in U.S. travelers

Male gender 24 (41)
Age, median (minimum-maximum) 64 (15–82)
Regiona
 Mexico, Caribbean, & Central America 18 (31)
 Asia 17 (29)
 Africa 16 (28)
 Europe 5 (9)
 South America 2 (3)
 North America 2 (3)
Purpose of travela
 Vacation 43 (74)
 Visiting friends and relatives 10 (17)
 Other (missionary/volunteer) 5 (9)
 Deployment and military duty 4 (7)
 School 1 (2)
Duration of travel, median (minimum-maximum) 12 days (6–105)
Living conditionsa
 Hotel 36 (62)
 Friends and relatives 13 (22)
 Group livingb 10 (17)
 Boat/cruise 7 (12)
Local water ingestion during travel 27 (47)
Water exposures during travel 20 (34)
Antimicrobial exposure since enrollment 23 (40)
 Malaria chemoprophylaxis 22 (38)
  Atovaquone/Proguanil 17 (29)
  Doxycycline 3 (5)
  Chloroquine 2 (3)
 Antibiotics for traveler’s diarrhea since enrollment 3 (5)
  Ciprofloxacin 2 (3)
  Erythromycin 1 (2)
 Systemic antibiotics for other indications since enrollment 3 (5)
  Azithromycin 1 (2)
  Cephalexin 1 (2)
  Unknown antibiotic 1 (2)
Illness since enrollment 13 (22)
Duration of illness, median (minimum-maximum) 4 days (1–27)
  1. aPercentages greater than 100 as someone can be counted more than once based upon region of travel or living conditions
  2. bGroup living included barracks, dorms, or kibbutz